Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Garrido

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Advances in Experimental Medicine and Biology|May 30, 2019
HLA Class-I Expression and Cancer ImmunotherapyFederico Garrido
Advances in Experimental Medicine and Biology|May 30, 2019
IntroductionFederico Garrido
Advances in Experimental Medicine and Biology|May 30, 2019
MHC/HLA Class I Loss in Cancer CellsFederico Garrido
Advances in Experimental Medicine and Biology|May 30, 2019
HLA Class-II Expression in Human TumorsFederico Garrido
Immunology|September 12, 2019
Cancer immune escape: MHC expression in primary tumours versus metastasesFederico Garrido, Natalia Aptsiauri
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and HopesNatalia Aptsiauri, Federico Garrido
Journal for Immunotherapy of Cancer|April 21, 2016
Targetless T cells in cancer immunotherapyPer Thor Straten, Federico Garrido
International Journal of Cancer|February 24, 2010
"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapyFederico Garrido, Teresa Cabrera, Natalia Aptsiauri
Journal of Cellular Physiology|April 22, 2003
MHC class I antigens, immune surveillance, and tumor immune escapeAngel Garcia-Lora, Ignacio Algarra, Federico Garrido
Current Opinion in Immunology|March 24, 2018
The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responsesNatalia Aptsiauri, Francisco Ruiz-Cabello, Federico Garrido
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Advances in Experimental Medicine and Biology|May 30, 2019
HLA Class-I Expression and Cancer ImmunotherapyFederico Garrido
Advances in Experimental Medicine and Biology|May 30, 2019
IntroductionFederico Garrido
Advances in Experimental Medicine and Biology|May 30, 2019
MHC/HLA Class I Loss in Cancer CellsFederico Garrido
Advances in Experimental Medicine and Biology|May 30, 2019
HLA Class-II Expression in Human TumorsFederico Garrido
Immunology|September 12, 2019
Cancer immune escape: MHC expression in primary tumours versus metastasesFederico Garrido, Natalia Aptsiauri
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and HopesNatalia Aptsiauri, Federico Garrido
Journal for Immunotherapy of Cancer|April 21, 2016
Targetless T cells in cancer immunotherapyPer Thor Straten, Federico Garrido
International Journal of Cancer|February 24, 2010
"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapyFederico Garrido, Teresa Cabrera, Natalia Aptsiauri
Journal of Cellular Physiology|April 22, 2003
MHC class I antigens, immune surveillance, and tumor immune escapeAngel Garcia-Lora, Ignacio Algarra, Federico Garrido
Current Opinion in Immunology|March 24, 2018
The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responsesNatalia Aptsiauri, Francisco Ruiz-Cabello, Federico Garrido
Pageof 10